false
0002079272
0002079272
2026-11-10
2026-11-10
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities
Exchange Act of 1934
Date of Report (Date of earliest event reported):
November 10, 2026
LAKEWOOD-AMEDEX BIOTHERAPEUTICS INC.
(Exact name of registrant as specified in its charter)
| Nevada |
|
001-43239 |
|
20-5274304 |
(State or other jurisdiction
of incorporation) |
|
(Commission File Number) |
|
(IRS Employer
Identification No.) |
8031 Cooper Creek Blvd., Unit 103, University Park, Florida 34201
(Address of principal executive offices) (Zip Code)
(941) 225-2515
(Registrant’s telephone number, including
area code)
N/A
(Former name or former address, if changed since
last report)
Check the appropriate box below if the Form 8-K
filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ☐ | Written communications pursuant to Rule 425 under the Securities
Act (17 CFR 230.425) |
| ☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange
Act (17 CFR 240.14a-12) |
| ☐ | Pre-commencement communications pursuant to Rule 14d-2(b)
under the Exchange Act (17 CFR 240.14d-2(b)) |
| ☐ | Pre-commencement communications pursuant to Rule 13e-4(c)
under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class |
|
Trading Symbol(s) |
|
Name of each exchange on which registered |
| Common Stock, par value $0.0001 per share |
|
LABT |
|
The Nasdaq Stock Market LLC |
Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR 230.405) or Rule 12b-2 of the Securities Exchange
Act of 1934 (17 CFR 240.12b-2).
Emerging growth company ☒
If an emerging growth company, indicate by check
mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act.
Item 3.01 Notice of Delisting or Failure to Satisfy a Continued
Listing Rule or Standard; Transfer of Listing.
On November 10, 2026, Lakewood-Amedex Biotherapeutics
Inc. (the “Company”) received a letter from the Listing Qualifications Department (the “Staff”) of The Nasdaq
Stock Market LLC (“Nasdaq”) notifying the Company that, for the 30 consecutive business days from September 29, 2026 through
November 9, 2026, the closing bid price of the Company’s common stock had been below $1.00 per share, the minimum required for continued
listing on The Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2) (the “Bid Price Rule”).
Because the Company effected a 1-for-10 reverse stock split on June 22, 2026, within the prior one-year period,
the Company is not eligible for a compliance period under Nasdaq Listing Rule 5810(c)(3)(A)(iv), and the Staff has determined to delist
the Company’s securities. Unless the Company requests a hearing by November 17, 2026, trading of the Company’s common stock
will be suspended at the opening of business on November 19, 2026, and Nasdaq will file a Form 25-NSE with the Securities and Exchange
Commission to remove the Company’s securities from listing and registration on Nasdaq.
The Company intends to timely request a hearing before a Nasdaq Hearings
Panel (the “Panel”), which will stay the suspension of the Company’s securities and the filing of the Form 25-NSE pending
the Panel’s decision. At the hearing, the Company intends to present a plan to regain compliance with the Bid Price Rule, which
may include a reverse stock split. There can be no assurance that the Panel will grant the Company’s request for continued listing
or that the Company will regain compliance.
Forward-Looking Statements
This Current Report on Form 8-K contains forward-looking
statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the Company’s
intention to request a hearing, the outcome of any hearing, and the Company’s plans to regain compliance with the Bid Price Rule.
These statements are subject to risks and uncertainties that could cause actual results to differ materially, including the risk that
the Panel may not grant the Company’s request for continued listing, that a reverse stock split may not result in compliance with
the Bid Price Rule, and that the Company’s common stock may be delisted from Nasdaq, as well as those described in the Company’s
filings with the Securities and Exchange Commission. The Company undertakes no obligation to update any forward-looking statement, except
as required by law.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
| Exhibit No. |
|
Description |
| 104 |
|
Cover Page Interactive Data File (embedded within the Inline XBRL document). |
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| |
LAKEWOOD-AMEDEX BIOTHERAPEUTICS INC. |
| |
|
|
| Date: November 16, 2026 |
By: |
/s/ Kelvin Cooper |
| |
Name: |
Kelvin Cooper |
| |
Title: |
Chief Executive Officer |